[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EE05305B1 - Zolmitriptaani sisaldav ravimpreparaat, meetod selle valmistamiseks ning seda sisaldav intranasaalse manustamise vahend - Google Patents

Zolmitriptaani sisaldav ravimpreparaat, meetod selle valmistamiseks ning seda sisaldav intranasaalse manustamise vahend

Info

Publication number
EE05305B1
EE05305B1 EEP200200283A EEP200200283A EE05305B1 EE 05305 B1 EE05305 B1 EE 05305B1 EE P200200283 A EEP200200283 A EE P200200283A EE P200200283 A EEP200200283 A EE P200200283A EE 05305 B1 EE05305 B1 EE 05305B1
Authority
EE
Estonia
Prior art keywords
pharmaceutical formulation
intranasal administration
preparation
zolmitriptan
formulation containing
Prior art date
Application number
EEP200200283A
Other languages
English (en)
Estonian (et)
Inventor
Roy Dearn Alan
Louise Williamson Sarah
John Summers Simon
John Coomber Trevor
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10865629&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE05305(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of EE200200283A publication Critical patent/EE200200283A/xx
Publication of EE05305B1 publication Critical patent/EE05305B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EEP200200283A 1999-12-03 2000-11-28 Zolmitriptaani sisaldav ravimpreparaat, meetod selle valmistamiseks ning seda sisaldav intranasaalse manustamise vahend EE05305B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9928578.5A GB9928578D0 (en) 1999-12-03 1999-12-03 Pharmaceutical formulations
PCT/GB2000/004528 WO2001039772A1 (en) 1999-12-03 2000-11-28 Pharmaceutical formulations containing zolmitriptan

Publications (2)

Publication Number Publication Date
EE200200283A EE200200283A (et) 2003-06-16
EE05305B1 true EE05305B1 (et) 2010-06-15

Family

ID=10865629

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200283A EE05305B1 (et) 1999-12-03 2000-11-28 Zolmitriptaani sisaldav ravimpreparaat, meetod selle valmistamiseks ning seda sisaldav intranasaalse manustamise vahend

Country Status (28)

Country Link
US (2) US6750237B1 (no)
EP (1) EP1237551B1 (no)
JP (1) JP2003515559A (no)
KR (1) KR100670092B1 (no)
CN (1) CN1222287C (no)
AT (1) ATE291914T1 (no)
AU (1) AU778092B2 (no)
BR (1) BRPI0016138B8 (no)
CA (1) CA2392050C (no)
CZ (1) CZ301528B6 (no)
DE (1) DE60019162T2 (no)
EE (1) EE05305B1 (no)
ES (1) ES2236001T3 (no)
GB (2) GB9928578D0 (no)
HK (3) HK1048442B (no)
HU (1) HU229458B1 (no)
IL (2) IL149578A0 (no)
IS (1) IS2135B (no)
MX (1) MXPA02005319A (no)
NO (1) NO322119B1 (no)
NZ (1) NZ518862A (no)
PL (1) PL200679B1 (no)
PT (1) PT1237551E (no)
RU (1) RU2255736C2 (no)
SK (1) SK287228B6 (no)
UA (1) UA75059C2 (no)
WO (1) WO2001039772A1 (no)
ZA (1) ZA200203704B (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8465468B1 (en) 2000-06-29 2013-06-18 Becton, Dickinson And Company Intradermal delivery of substances
GB9928578D0 (en) * 1999-12-03 2000-02-02 Zeneca Ltd Pharmaceutical formulations
SE0102855D0 (sv) * 2001-08-27 2001-08-27 Astrazeneca Ab Method of treatment
US20050256182A1 (en) * 2004-05-11 2005-11-17 Sutter Diane E Formulations of anti-pain agents and methods of using the same
WO2005115345A1 (en) * 2004-05-28 2005-12-08 Imaginot Pty Ltd Oral therapeutic compound delivery system
US8216610B2 (en) 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
EP1812428A2 (en) * 2004-11-19 2007-08-01 Teva Pharmaceutical Industries Ltd Zolmitriptan crystal forms
CN100341504C (zh) * 2004-12-01 2007-10-10 鲁南制药集团股份有限公司 佐米曲普坦速释制剂
EP3263117A1 (en) * 2005-11-28 2018-01-03 Imaginot Pty Ltd. Oral therapeutic compound delivery system
WO2008016678A2 (en) * 2006-08-01 2008-02-07 Sunesis Pharmaceuticals, Inc. Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
BRPI0715579A2 (pt) * 2006-10-19 2015-05-26 Auspex Pharmaceuticals Inc "composto, composição farmacêutica e uso de um composto"
KR101517415B1 (ko) * 2008-05-14 2015-05-07 에스케이바이오팜 주식회사 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물
AU2011316225B2 (en) 2010-10-15 2016-05-19 Contera Pharma Aps Combinations of serotonin receptor agonists for treatment of movement disorders
JP6121734B2 (ja) * 2012-02-09 2017-04-26 久光製薬株式会社 マイクロニードル用ゾルミトリプタン含有コーティング組成物及びマイクロニードルデバイス
HUE037732T2 (hu) 2012-04-18 2018-09-28 Contera Pharma Aps A mozgászavarok fejlett kezelésére alkalmas, szájon át szedhetõ gyógyszerészeti készítmény
US11554229B2 (en) 2013-03-26 2023-01-17 OptiNose Inc. Nasal administration
KR101624049B1 (ko) 2014-10-29 2016-05-24 연세대학교 산학협력단 사카린을 이용한 용해도를 증가시킨 약제학적 조성물
CN108135916B (zh) * 2015-06-19 2022-01-28 北京科辉智药生物科技有限责任公司 手性特异性含硼化合物及其在治疗癌症或淀粉样变性中的应用
WO2017122161A1 (en) 2016-01-15 2017-07-20 Cadila Healthcare Limited An intranasal composition comprising 5ht1b/1d receptor agonists
EP3481385A1 (en) 2016-07-11 2019-05-15 Contera Pharma APS Pulsatile drug delivery system for treating morning akinesia
WO2019126766A1 (en) * 2017-12-21 2019-06-27 Taiwan Liposome Co., Ltd. Sustained-release triptan compositions and method of use the same through subdermal route or the like
US20210322343A1 (en) 2020-04-15 2021-10-21 Farzana Shaheen Nasally administered pharmaceutical composition for the treatment of epilepsy and related disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ238424A (en) * 1990-06-07 1993-12-23 Wellcome Found 3,5-substituted indole derivatives; medicaments and preparatory processes.
JP2000505090A (ja) * 1996-07-11 2000-04-25 ファーマーク、ニーダーランド、ベスローテン、フェンノートシャップ インドール選択的セロトニンアゴニストを含む包接錯体
GB2315673A (en) * 1996-08-01 1998-02-11 Merck & Co Inc Treatment of migraine
DE59804534D1 (de) * 1997-02-05 2002-07-25 Jago Res Ag Muttenz Medizinische aerosolformulierungen
GB9928578D0 (en) * 1999-12-03 2000-02-02 Zeneca Ltd Pharmaceutical formulations

Also Published As

Publication number Publication date
US20040214899A1 (en) 2004-10-28
NZ518862A (en) 2004-02-27
SK7532002A3 (en) 2002-12-03
CZ301528B6 (cs) 2010-04-07
NO20022525D0 (no) 2002-05-28
EP1237551B1 (en) 2005-03-30
HUP0203597A3 (en) 2005-07-28
HK1048442A1 (en) 2003-04-04
ATE291914T1 (de) 2005-04-15
IL149578A (en) 2008-04-13
IL149578A0 (en) 2002-11-10
NO322119B1 (no) 2006-08-14
KR20020058051A (ko) 2002-07-12
GB2373726A (en) 2002-10-02
MXPA02005319A (es) 2002-12-06
RU2255736C2 (ru) 2005-07-10
HU229458B1 (en) 2013-12-30
EP1237551A1 (en) 2002-09-11
HK1048442B (zh) 2005-05-13
BR0016138B1 (pt) 2013-09-10
HUP0203597A2 (hu) 2003-02-28
US6750237B1 (en) 2004-06-15
PT1237551E (pt) 2005-07-29
PL357597A1 (en) 2004-07-26
ZA200203704B (en) 2003-10-29
NO20022525L (no) 2002-05-28
DE60019162D1 (de) 2005-05-04
CA2392050A1 (en) 2001-06-07
DE60019162T2 (de) 2006-02-02
KR100670092B1 (ko) 2007-01-17
GB2373726B (en) 2004-10-20
HK1048445A1 (en) 2003-04-04
BR0016138A (pt) 2002-08-06
RU2002117649A (ru) 2004-01-27
AU1715701A (en) 2001-06-12
JP2003515559A (ja) 2003-05-07
IS6394A (is) 2002-05-24
GB0214845D0 (en) 2002-08-07
SK287228B6 (sk) 2010-03-08
IS2135B (is) 2006-08-15
GB9928578D0 (en) 2000-02-02
HK1048445B (zh) 2005-08-26
HK1053430A1 (en) 2003-10-24
UA75059C2 (uk) 2006-03-15
PL200679B1 (pl) 2009-01-30
CA2392050C (en) 2009-11-24
AU778092B2 (en) 2004-11-18
CN1402636A (zh) 2003-03-12
US7220767B2 (en) 2007-05-22
CN1222287C (zh) 2005-10-12
CZ20021901A3 (cs) 2002-11-13
WO2001039772A1 (en) 2001-06-07
ES2236001T3 (es) 2005-07-16
EE200200283A (et) 2003-06-16
BRPI0016138B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
EE05305B1 (et) Zolmitriptaani sisaldav ravimpreparaat, meetod selle valmistamiseks ning seda sisaldav intranasaalse manustamise vahend
TR200002773T2 (tr) Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
TW200500083A (en) Formulation of human antibodies for treating tnf-α associated disorders
DE60022692D1 (de) (S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen
IL144294A0 (en) P53 inhibitors and therapeutic use of the same
ITMI20010562A1 (it) Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari
SG128415A1 (en) Device for liquid treatment of wafer-shaped articles
NO20011440L (no) mGluR5-antagonister for behandling av smerte og angst
CY1107531T1 (el) Χρηση αναστολεων πρωτεασομης για την αγωγη των διαταραχων ξηρου οφθαλμου
NO20004419L (no) Ny anvendelse
NZ509762A (en) 5-Azatricyclo[3.3.1.1<3,7>]decane derivatives, pharmaceuticals thereof, and their use as cholinergic receptor agonists and antagonists
EE05168B1 (et) N-guanidinoalklamiid, meetod selle valmistamiseks, seda sisaldav farmatseutiline preparaat ning raviotstarbeline kasutamine
SE0001916D0 (sv) Novel formulation
BG105984A (bg) Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението
SE0002353D0 (sv) New use
SE0202365D0 (sv) New formulation and use thereof
DE60004819D1 (de) 10-formyltetrahydrofolate dehydrogenase als therapeutischen mittel

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20101231